BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22268396)

  • 1. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy.
    Vona-Davis L; Rose DP
    Curr Diabetes Rev; 2012 Mar; 8(2):116-30. PubMed ID: 22268396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and Breast Cancer: Molecular Targets.
    Faria J; Negalha G; Azevedo A; Martel F
    J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between menopausal status and obesity in affecting breast cancer risk.
    Rose DP; Vona-Davis L
    Maturitas; 2010 May; 66(1):33-8. PubMed ID: 20181446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
    Wysocki PJ; Wierusz-Wysocka B
    Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
    Fuentes-Mattei E; Velazquez-Torres G; Phan L; Zhang F; Chou PC; Shin JH; Choi HH; Chen JS; Zhao R; Chen J; Gully C; Carlock C; Qi Y; Zhang Y; Wu Y; Esteva FJ; Luo Y; McKeehan WL; Ensor J; Hortobagyi GN; Pusztai L; Fraser Symmans W; Lee MH; Yeung SC
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
    Ligibel JA; Strickler HD
    Am Soc Clin Oncol Educ Book; 2013; ():52-9. PubMed ID: 23714455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    Martinez JA; Chalasani P; Thomson CA; Roe D; Altbach M; Galons JP; Stopeck A; Thompson PA; Villa-Guillen DE; Chow HH
    BMC Cancer; 2016 Jul; 16():500. PubMed ID: 27430256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and breast cancer risk: a meta-analysis and critical literature review.
    Col NF; Ochs L; Springmann V; Aragaki AK; Chlebowski RT
    Breast Cancer Res Treat; 2012 Oct; 135(3):639-46. PubMed ID: 22847511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.
    Patterson RE; Marinac CR; Natarajan L; Hartman SJ; Cadmus-Bertram L; Flatt SW; Li H; Parker B; Oratowski-Coleman J; Villaseñor A; Godbole S; Kerr J
    Contemp Clin Trials; 2016 Mar; 47():64-71. PubMed ID: 26706665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females.
    Berstein LM; Vasilyev DA; Iyevleva AG; Boyarkina MP; Poroshina TE; Khadzhimba AS; Imyanitov EN
    Future Oncol; 2015; 11(5):759-70. PubMed ID: 25757680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Martin-Castillo B; Menendez JA
    Curr Mol Med; 2010 Oct; 10(7):674-91. PubMed ID: 20712585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin as an Anticancer Agent.
    Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
    Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
    Gallagher EJ; LeRoith D
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):485-94. PubMed ID: 23974779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does use of metformin protect against cancer in Type 2 diabetes mellitus?
    Bo S; Benso A; Durazzo M; Ghigo E
    J Endocrinol Invest; 2012 Feb; 35(2):231-5. PubMed ID: 22490993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
    Hankinson SJ; Fam M; Patel NN
    Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes.
    Adamia N; Virsaladze D; Charkviani N; Skhirtladze M; Khutsishvili M
    Georgian Med News; 2007 Apr; (145):52-5. PubMed ID: 17525501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metformin - new data for an "old", but efficient, safe and reliable antidiabetic drug].
    Winkler G
    Orv Hetil; 2016 Jun; 157(23):882-91. PubMed ID: 27233831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.